Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-01-26Clinical Trial Update: RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder [Phase 2]
Phase 2 clinical trial update for RP5063 in schizophrenia and schizoaffective disorder. The study completed and results were posted in Janua…
-
CLINICAL_TRIALS trial_result · 2015-01-22Clinical Trial Update: Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia [Phase 4]
A Phase 4 trial assessing the effectiveness and safety of amisulpride in Chinese patients with schizophrenia has been completed and results …
-
FDA approval · 2015-01-20FDA Approved: OLANZAPINE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for the generic olanzapine, manufactured by Dr. Reddy's Laboratories Inc.
-
FDA approval · 2015-01-17FDA Approved: OLANZAPINE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved Torrent Pharmaceuticals Limited's supplemental application for olanzapine (generic) under the ANDA pathway. This represents a s…
-
CLINICAL_TRIALS trial_result · 2015-01-16Clinical Trial Update: To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox [Phase 2]
A Phase 2 clinical trial update reporting completion of a study evaluating how treatment interruption affects re-initiation of bifeprunox in…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-01-16Clinical Trial Update: Bifeprunox in the Treatment of Schizophrenia [Phase 3]
The Phase 3 clinical trial evaluating bifeprunox for schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2015-01-16Clinical Trial Update: Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia [Phase 2]
Phase 2 study evaluating twice-daily titration of bifeprunox in schizophrenia and schizoaffective disorder has completed.
-
CLINICAL_TRIALS trial_result · 2015-01-16Clinical Trial Update: Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder [Phase 2]
Phase 2 trial update examining progressively decreasing titration schedules of bifeprunox in individuals with schizophrenia or bipolar disor…
-
CLINICAL_TRIALS trial_result · 2015-01-16Clinical Trial Update: Nicotine Effects on Endophenotypes of Schizophrenia [NA]
A completed clinical trial evaluating nicotine effects on endophenotypes in schizophrenia; results have been posted.
-
CLINICAL_TRIALS trial_result · 2015-01-12Clinical Trial Update: Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics [Phase 1]
Phase 1 study evaluating safety, tolerability, PK and PD of EVP-6308 and its potential to affect the PK of concomitant antipsychotic therapy…
-
FDA approval · 2015-01-12FDA Approved: RISPERIDONE — Original Application (Chartwell RX, LLC)
FDA approved Chartwell RX, LLC's generic risperidone through an original ANDA submission, marking the first approval of this generic product…
-
CLINICAL_TRIALS trial_result · 2015-01-08Clinical Trial Update: Evaluation of the In SHAPE Fitness Intervention for Adults With Serious Mental Illness [NA]
Clinical trial update on the In SHAPE fitness intervention for adults with serious mental illness indicates the study status is COMPLETED. T…
-
CLINICAL_TRIALS trial_result · 2015-01-08Clinical Trial Update: Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI [NA]
This ClinicalTrials.gov update reports that the statewide program to prevent early mortality and promote fitness in persons with serious men…
-
FDA approval · 2015-01-05FDA Approved: LATUDA — Supplemental Application (Sumitomo Pharma America, Inc.)
The FDA approved a supplemental application for LATUDA (lurasidone hydrochloride) submitted by Sumitomo Pharma America, Inc.
-
FDA approval · 2015-01-05FDA Approved: ABILIFY MAINTENA — Supplemental Application (Otsuka America Pharmaceutical, Inc.)
FDA approves a supplemental application for ABILIFY MAINTENA (aripiprazole) submitted by Otsuka America Pharmaceutical, Inc.
-
CLINICAL_TRIALS trial_result · 2014-12-24Clinical Trial Update: Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis [Phase 4]
Status update for a Phase 4 clinical trial evaluating early pharmacological and psychological interventions for late prodromal states of psy…
-
CLINICAL_TRIALS trial_result · 2014-12-23Clinical Trial Update: Patient-Centered Medication Adherence Intervention for Schizophrenia [NA]
This completed study reports results from a patient-centered intervention designed to improve medication adherence in people with schizophre…
-
FDA approval · 2014-12-20FDA Approved: OLANZAPINE — Supplemental Application (Dr. Reddy's Laboratories Ltd.)
FDA approved Dr. Reddy's Laboratories Ltd.'s supplemental application for olanzapine, enabling a generic olanzapine product.
-
FDA approval · 2014-12-19FDA Approved: CLOZARIL — Supplemental Application (HLS Therapeutics (USA), Inc.)
FDA approved a supplemental application for Clozaril (clozapine) submitted by HLS Therapeutics (USA), Inc.
-
FDA approval · 2014-12-19FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)
FDA approved a supplemental application for ZYPREXA RELPREVV (olanzapine pamoate) submitted by H2-Pharma LLC.
-
CLINICAL_TRIALS trial_result · 2014-12-17Clinical Trial Update: Study in Adolescents With Schizophrenia or Bipolar Disorder [Phase 4]
Phase 4 clinical trial in adolescents with schizophrenia or Bipolar I Disorder has completed and results were posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-12-16Clinical Trial Update: Neuroplasticity-oriented Cognitive Intervention in Early Onset and First Admission Schizophrenia [NA]
Completed clinical trial evaluating a neuroplasticity-oriented cognitive intervention for schizophrenia, including early onset and first-epi…
-
FDA approval · 2014-12-13FDA Approved: PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for a generic Perphenazine and Amitriptyline Hydrochloride product manufactured by Mylan Pharmac…
-
FDA approval · 2014-12-13FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Clozapine from Mylan Pharmaceuticals Inc., granting changes to the product labeling under th…
-
FDA approval · 2014-12-10FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
The FDA approved Viatris Specialty LLC's supplemental application for Geodon (ziprasidone mesylate).